IL TIMING PER LA COLECISTECTOMIA DOPO PANCREATITE BILIARE. L’INTERVENTO PRECOCE ENTRO 14 GG PUO’ COMPORTARE UN AUMENTO DELLA MORTALITA’. UN GRANDE STUDIO ITALIANO RETROSPETTIVO. DA “JAMA SURGERY”

CHIRURGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, METODOLOGIA, NEWSLETTER, Senza categoria

Timing of Cholecystectomy After Moderate and Severe Acute Biliary Pancreatitis Marcello Di Martino et al. IMPORTANCE Considering the lack of equipoise regarding the timing of cholecystectomy in patients with moderately severe and severe acute biliary pancreatitis (ABP), it is critical to assess this issue. OBJECTIVE To assess the outcomes of early cholecystectomy (EC) in patients…

LA GRAN PARTE DEI 23.000 TRIAL REGISTRATI NEL COCHRANE DATABASE HA CONCLUSIONI LARGAMENTE SOVRAVALUTATE: VERSO UNA RILETTURA DEL POTERE DEL “P VALUE” ! DA “NEJM Evid “

GASTROENTEROLOGIA, MEDICINA INTERNA, METODOLOGIA, Senza categoria

A New Look at P Values for Randomized Clinical Trials Erik van Zwet, et al. Abstract BACKGROUND We have examined the primary efficacy results of 23,551 randomized clinical trials from the Cochrane Database of Systematic Reviews. METHODS We estimate that the great majority of trials have much lower statistical power for actual effects than the…

ANTIDEPRESSIVI TRICICLICI PER IL COLON IRRITABILE: IL COMMENTO DI PHILIP SCHOENFELD SUL TRIAL “ATLANTIS” (Lancet 2023; 402: 1773-85.)-DA “EVIDENCE-BASED GI, AN ACG PUBLICATION” (FREE) (COPIONI!)

GASTROENTEROLOGIA, IBS, MEDICI DI FAMIGLIA, MEDICINA INTERNA, Senza categoria

Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS study Philip Schoenfeld  This summary reviews Ford AC, Wright-Hughes A, Alderson S, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2023; 402: 1773-85. Correspondence…

PROBIOTICI COME TERAPIA ADDIZIONALE PER LA DEPRESSIONE. UN INTERESSANTE TRIAL RANDOMIZZATO INGLESE. DA “JAMA PSYCHIATRY” (FREE)

GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA DEI PROBIOTICI, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression. A Randomized Clinical Trial. Viktoriya L. Nikolova  et al.    Abstract Importance  The microbiota-gut-brain axis is a promising target for novel treatments for mood disorders, such as probiotics. However, few clinical trials have been conducted, and further safety and…

EMERGENZA CHIRURGICA ADDOMINALE: LE LINEE GUIDA “CESENA” IN FAVORE DELL’APPROCCIO PRELIMINARE LAPAROSCOPICO ! UNA REVIEW SU 343 TRA META-ANALISI E TRIAL. DA “World Journal of Emergency Surgery” (FREE)

CHIRURGIA, LINEE GUIDA EBM, NEWSLETTER

Cesena guidelines: WSES consensus statement on laparoscopic-first approach to general surgery emergencies and abdominal trauma Giacomo Sermonesi et al. BACKGROUND: Laparoscopy is widely adopted across nearly all surgical subspecialties in the elective setting. Initially finding indication in minor abdominal emergencies, it has gradually become the standard approach in the majority of elective general surgery procedures. Despite…

RISCHIO DI EVENTI AVVERSI GASTROINTESTINALI CON GLI AGONISTI DEL RECETTORE PER IL GLUCAGONE (GLP-1) PER IL DIABETE ED IL CALO PONDERALE. UNA REVISIONE DA”JAMA” (FREE)

EPATOLOGIA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Mohit Sodhi et al Glucagon-like peptide 1 (GLP-1) agonists are medications approved for treatment of diabetes that recently have also been used off label for weight loss.1 Studies have found increased risks of gastrointestinal adverse events (biliary disease,2 pancreatitis,3 bowel obstruction,4 and gastroparesis5) in patients…